{"id":348,"date":"2026-09-08T23:25:56","date_gmt":"2026-09-08T18:25:56","guid":{"rendered":"https:\/\/medlinkanalytics.com\/blog\/?p=348"},"modified":"2026-09-08T23:25:57","modified_gmt":"2026-09-08T18:25:57","slug":"wasteful-and-inappropriate-service-reduction-model","status":"publish","type":"post","link":"https:\/\/medlinkanalytics.com\/blog\/wasteful-and-inappropriate-service-reduction-model\/","title":{"rendered":"Wasteful and Inappropriate Service Reduction Model"},"content":{"rendered":"
\"Wasteful<\/figure>\n\n\n

Inside CMS’s WISeR Model: What AI-Driven Prior Authorization in Traditional Medicare Means for Providers<\/strong><\/p>\n\n\n\n

The Wasteful and Inappropriate Service Reduction (WISeR) Model is a six-state CMS Innovation Center pilot, running January 2026 through December 2031, that introduces AI-assisted prior authorization into traditional Medicare for the first time. Six technology vendors, one per state in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington, use AI and machine learning to screen requests for 13 services CMS considers vulnerable to fraud, waste, and abuse, including skin and tissue substitutes, knee arthroscopy, and electrical nerve stimulator implants. CMS requires that any non-payment recommendation be made by a licensed clinician, not AI alone, but the model has already drawn a Senate repeal vote, a House defunding effort, and a formal corrective action order against one of its six vendors after providers reported prior authorization delays of four to eight weeks against a required 72-hour standard. As of August 2026, CMS still has not released the model’s actual denial, appeal, or overturn rate data.<\/p>\n\n\n\n

Prior authorization has been a fixture of Medicare Advantage for years. Traditional, fee-for-service Medicare had almost entirely avoided it, until January 1, 2026, when CMS launched the WISeR Model as the first Innovation Center pilot built entirely around private technology vendors. Eight months in, it has become one of the most closely watched, and contested, programs in U.S. healthcare policy, and it’s directly relevant to any practice billing traditional Medicare for the affected service categories.<\/p>\n\n\n\n

What WISeR Actually Does<\/h2>\n\n\n\n

CMS’s Center for Medicare and Medicaid Innovation (CMMI) introduced WISeR on June 27, 2025, framing it as a test of whether AI and machine learning, paired with required clinician review, can reduce spending on services the agency considers prone to overuse and improper billing. The model is built on two data points CMS cites as justification: national estimates that waste accounts for up to 25% of U.S. healthcare spending, and geographic spending variation on the model’s targeted services that ranged from $202 to $748 per capita by state in 2024, variation driven largely by skin and tissue substitute products applied to chronic wounds.<\/p>\n\n\n\n

Six technology vendors were selected, each assigned exclusively to one pilot state. Within those states, providers now face a review step for a defined list of mostly outpatient procedures, including skin and tissue substitutes, electrical nerve stimulator implants, knee arthroscopy for osteoarthritis, epidural steroid injections, cervical fusion, and treatments for urinary incontinence and impotence. Inpatient-only services, emergency care, and anything that would pose substantial risk to a patient if delayed are excluded from the model. Medicare Advantage is not affected, this applies only to traditional fee-for-service Medicare.<\/p>\n\n\n\n

Providers have a choice in how the review happens. They can request prior authorization before treating the patient, guaranteeing payment if approved, but requiring the patient to wait on a decision, or treat first and have the claim reviewed before payment, which avoids delaying care but risks non-payment if the review later finds the service didn’t meet Medicare’s criteria. What Medicare covers and what it pays remain unchanged; the model only adds a review layer.<\/p>\n\n\n\n

Critically, CMS’s design does not permit AI to deny a claim on its own. Any recommendation of non-payment must be made by an appropriately licensed clinician, and coverage decisions are required within 72 hours – 48 hours for expedited requests.<\/p>\n\n\n\n

Why the Model Is Under So Much Scrutiny<\/h2>\n\n\n\n

The most consequential test of WISeR’s first year came on July 16, 2026, when the Senate voted 46-50 along party lines against advancing a resolution to repeal the model, following a Congressional Review Act process triggered after the Government Accountability Office ruled WISeR was subject to a repeal vote. About five weeks earlier, the House Appropriations Committee had already passed an amendment to defund the program in fiscal 2027, a fight that resumes this fall as part of broader spending negotiations. The model survived its first major political test, but its funding remains genuinely contested heading into FY2027.<\/p>\n\n\n\n

Senators Ron Wyden, Maria Cantwell, Richard Blumenthal, and Kirsten Gillibrand led the repeal effort, arguing the model lets contractors use AI to delay and deny care that traditional Medicare has historically covered without this level of review. Rep. Suzan DelBene has been more direct, calling the model “a Trojan horse for privatizing Medicare.” CMS Innovation Center Director Abe Sutton pushed back on a related criticism, that vendors are paid a percentage of “averted expenditures,” which critics say incentivizes denials, stating in an October 2025 AMA-co-hosted webinar that contractors are not incentivized to deny claims but to “get the determination right,” and noting that physicians retain their existing appeal rights regardless of the model.<\/p>\n\n\n\n

What Happened in Washington State<\/h2>\n\n\n\n

The clearest documented breakdown in the model’s operations occurred in Washington, where the state’s assigned vendor is Virtix Health. In an April 2026 letter to HHS Secretary Robert F. Kennedy Jr., Senator Maria Cantwell reported that providers were waiting 15 to 20 days for determinations , well outside the required 72-hour window , and that procedures typically completed within two weeks were instead taking four to eight weeks. The vendor has disputed that characterization of its turnaround times.<\/p>\n\n\n\n

In late June 2026, CMS ordered Virtix Health to submit a formal Corrective Action Plan after determining the vendor failed to meet required review turnaround standards , the first public acknowledgment from CMS of operational failure within the pilot. In a June statement to Seattle public radio station KUOW confirming the corrective action plan, CMS reported that prior authorization turnaround, which had averaged roughly five days over the program’s first four months, had since fallen to 1.7 days , inside the 72-hour standard , with pre-payment reviews averaging just over three days. CMS’s statement did not clarify whether those improved figures applied to Washington specifically or across all six pilot states, and the agency is reviewing the vendor’s progress every two weeks.<\/p>\n\n\n\n

The Data Gap That’s Fueling the Debate<\/h2>\n\n\n\n

Nearly eight months into the pilot, CMS has not published denial, appeal, or overturn rate data for WISeR, figures that would allow independent verification of both the program’s critics and CMS’s own assurances. In June 2026, 31 House Democrats formally requested this implementation data from CMS Administrator Mehmet Oz, including denial rates, appeal outcomes, and turnaround times, with a July 15 deadline that appears to have passed without public release.<\/p>\n\n\n\n

The concern driving that request has a specific precedent: in Medicare Advantage, KFF reporting found that only 11.5% of denied prior authorization requests were appealed in 2024, but 80.7% of those appeals were partially or fully overturned , a pattern suggesting a meaningful share of MA denials may not have been appropriate in the first place, and that most patients and providers don’t challenge denials even when they likely would win. Without published WISeR-specific data, it remains an open question whether the traditional Medicare pilot is following a similar pattern.<\/p>\n\n\n\n

What Providers in Pilot States Should Watch<\/h2>\n\n\n\n

For practices in Arizona, New Jersey, Ohio, Oklahoma, Texas, and Washington billing any of the 13 affected service categories, a few developments are worth tracking directly:<\/p>\n\n\n\n